Female Sexual Function in Castilla Y Leon (Spain): Normal Ranges

Royo, F. Castroviejo; Redondo, C. Conde; Toves, Luis Antonio Rodríguez; García-Tuñón, Carlos Marina; Tejero, Carmen González; Oceja, José María Martínez-Sagarra

doi:10.4172/2161-0932.1000240

Cited by 6 publications

(8 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Global sexual function results in a score ranging from 2 to 36 points, with a higher score indicating better sexual function. A cutoff 26.55 points or lower identifies women at risk of female sexual dysfunction …”

Section: Methodsmentioning

confidence: 99%

“…A cutoff 26.55 points or lower identifies women at risk of female sexual dysfunction. 17,18 Subjective Secondary Outcomes Dyspareunia | The intensity of dyspareunia was assessed in all patients (sexually active and inactive) at the baseline visit according to their last vaginal sexual activities. Patients were asked to complete a VAS ranging from 0 to 10, with higher score indicating worse dyspareunia.…”

Section: Primary Outcomementioning

confidence: 99%

See 1 more Smart Citation

Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause

et al. 2023

View full text Add to dashboard Cite

ImportanceSurvivors of breast cancer present more severe symptoms of genitourinary syndrome of menopause (GSM) than patients without history of breast cancer. Recently, new treatments, such as vaginal laser therapy, have appeared, but evidence of their efficacy remains scarce.ObjectiveTo assess the safety and efficacy of carbon dioxide (CO2) vs sham vaginal laser therapy after 6 months of follow-up in survivors of breast cancer with GSM receiving aromatase inhibitors.Design, Setting, and ParticipantsThis prospective double-blind sham-controlled randomized clinical trial with two parallel study groups was performed during October 2020 to March 2022 in a tertiary referral hospital. Survivors of breast cancer using aromatase inhibitors were assessed for eligibility, and eligible patients were randomized into the 2 treatment groups. Follow-up was conducted at 6 months. Data were analyzed in July 2022.InterventionsAll patients from both groups were instructed to use the first-line treatment (FLT) based on nonhormonal moisturizers and vaginal vibrator stimulation. Patients for each group were allocated to 5 monthly sessions of fractional CO2 laser therapy (CLT) or sham laser therapy (SLT).Main Outcomes and MeasuresThe primary outcome was sexual function, evaluated through Female Sexual Function Index (FSFI) score. Other subjective measures of efficacy included a visual analog scale of dyspareunia, vaginal pH, a Vaginal Health Index, quality of life (assessed via Short-Form 12), and body image (assessed with the Spanish Body Image Scale). Objective measures of efficacy included vaginal maturation index, vaginal epithelial elasticity (measured in Pascals) and vaginal epithelial thickness (measured in millimeters). Measures were assessed before and after the intervention. Tolerance (measured on a Likert scale), adverse effects, and estradiol levels were recorded.ResultsAmong 211 survivors of breast cancer assessed, 84 women were deemed eligible and 72 women (mean [SD] age, 52.6 [8.3] years) were randomized to CLT (35 participants) or SLT (37 participants) and analyzed. There were no statistically significant differences between groups at baseline. At 6 months, both groups showed improvement in FSFI (mean [SD] score at baseline vs 6 months: CLT, 14.8 [8.8] points vs 20.0 [9.5] points; SLT, 15.6 [7.0] points vs 23.5 [6.5] points), but there was no significant difference between CLT and SLT groups in the improvement of sexual function evaluated through the FSFI test overall (mean [SD] difference, 5.2 [1.5] points vs 7.9 [1.2] points; P = .15) or after excluding women who were not sexually active (mean [SD] difference, 2.9 [1.4] points vs 5.5 [1.1] points; P = .15). There were also no differences between improvement of the 2 groups at 6 months of follow-up in the other assessed subjective outcomes, including dyspareunia (mean [SD] difference, −4.3 [3.4] vs −4.5 [2.3]; P = .73), Vaginal Health Index (mean [SD] difference, 3.3 [4.1] vs 5.0 [4.5]; P = .17), body image (mean [SD] difference, −3.7 [4.5] vs −2.7 [4.8]; P = .35), and quality of life (mean [SD] difference, −0.3 [3.6] vs −0.7 [3.2]; P = .39). Similarly, there were no differences in improvements in objective outcomes, including vaginal pH (mean [SD] difference, −0.6 [0.9] vs −0.8 [1.2]; P = .29), vaginal maturation index (mean [SD] difference, 10.2 [17.4] vs 14.4 [17.1]; P = .15), vaginal epithelial thickness (mean [SD] difference, 0.021 [0.014] mm vs 0.013 [0.012] mm; P = .30), vaginal epithelial elasticity (mean [SD] difference, −1373 [3197] Pascals vs −2103 [3771] Pascals; P = .64). There were significant improvements in the overall analysis regardless of group in many outcomes. The 2 interventions were well tolerated, but tolerance was significantly lower in the CLT group than the SLT group (mean [SD] Likert scale score, 3.3 [1.3] vs 4.1 [1.0]; P = .007). No differences were observed in complications or serum estradiol levels.Conclusions and RelevanceIn this randomized clinical trial, vaginal laser treatment was found to be safe after 6 months of follow-up, but no statistically significant differences in efficacy were observed between CLT and SLT.Trial RegistrationClinicalTrials.gov identifier: NCT04619485

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Primary Outcomementioning

confidence: 99%

Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This demonstrates important differences compared with the general female population from the countries involved in the study – Brazil and Spain –, which presented sexual intercourse rates ranging from 83.6% to 85.3%. 15 16 Also, the prevalence of sexual dysfunction in the present study (84.3%), compared with a large Brazilian sample of non-SB women with dysfunction rates of 49%, highlights the need to improve sexual care in SB. 17 The weak median scores found in the overall and specific-domains of the FSFI-6 among our patients are similar to the scores found in previous studies that quantitatively assessed sexuality in a quantitative matter.…”

Section: Discussionmentioning

confidence: 56%

Sexuality of Female Spina Bifida Patients: Predictors of a Satisfactory Sexual Function

Motta

Bujons

Madarriaga

et al. 2021

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective To assess the sexual function of women with spina bifida (SB), and to verify the factors that influence their sexual function. Methods A cross-sectional study in which a validated female-specific questionnaire was applied to 140 SB female patients from four different cities (Porto Alegre, Brazil; and Barcelona, Madrid, and Málaga, Spain) between 2019 and 2020. The questionnaires collected data on the clinical characteristics of SB, and female sexual function was assessed using the 6-item version of the Female Sexual Function Index (FSFI-6) validated to Portuguese and Spanish. Results Half of the patients had had sexual activity at least once in the life, but most (57.1%) did not use any contraception method. Sexual dysfunction was present in most (84.3%) patients, and all sexual function domains were impaired compared those of non-neurogenic women. The presence of urinary and fecal incontinence significantly affected the quality of their sexual activity based on the FSFI-6. Conclusion The specific clinical aspects of the SB patients, such as urinary and fecal incontinence, should be properly addressed by their doctors, since they are associated with reduced sexual activity and lower FSFI-6 scores in the overall or specific domains. There is also a need to improve gynecological care among sexually-active SB patients, since most do not use any contraceptive methods and are at risk of inadvertent pregnancy.

show abstract

“…Sexual dysfunction is defined as psychophysiological changes in sexual cycle and may cause discomfort and personal problems. 17 The World Health Organization's International Statistical Classification of Disease and Related Health Problems (ICD-10) defines sexual dysfunction as a condition in which an individual cannot participate in desired sexual activity by each individual. 18…”

Section: Resultsmentioning

confidence: 99%

Profile of sexual function using Female Sexual Function Index (FSFI) in post-menopausal women in Geriatric Clinic, Dr Soetomo Hospital, Surabaya

Hurrahmi

et al. 2018

MOG

View full text Add to dashboard Cite

Objectives: to describe the profile of sexual function in post-menopausal women at Geriatric Clinic, Dr. Soetomo Hospital, Surabaya in May 2016 and to determine the factors of sexual dysfunction in 6 sexual domains.Materials and Methods: a descriptive study using survey to obtain data on the examined variables. Population in this study was all post-menopausal women at Geriatric Clinic of Dr. Soetomo Hospital, Surabaya, in May 2016. Data were obtained using Female Sexual Function Index (FSFI) questionnaire.Results: Total population in this study was 160 patients. The number of samples who met inclusion criteria were 90 patients, but only 37 were willing to participate. The prevalence of samples who were still active in sexual intercourse was 29.7%. Based on 6 sexual domains, the prevalence of the lack of desire was 48.6%, lack of arousal was 75.7%, lack of lubrication was 73%, lack of orgasm was 73%, lack of satisfaction was 73% and pain was 70.3%. The assessment of sexual function found that 78.4% of the samples were sexually dysfunctional.Conclusion: The high prevalence (78.4%) of sexual dysfunction in post-menopausal woman was caused by dysfunction in sexual domain.

show abstract

Female Sexual Function in Castilla Y Leon (Spain): Normal Ranges

Cited by 6 publications

References 9 publications

Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause

Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause

Sexuality of Female Spina Bifida Patients: Predictors of a Satisfactory Sexual Function

Profile of sexual function using Female Sexual Function Index (FSFI) in post-menopausal women in Geriatric Clinic, Dr Soetomo Hospital, Surabaya

Contact Info

Product

Resources

About